Kamada Ltd.

Seven of Amgen, Inc. ’s drugs will incur Medicare Part B price inflation rebates in the third quarter, including its blockbuster bone density treatment Prolia, according to a list released by the C

Israel-based Kamada Ltd. says biosimilars are a “key strategic focus in our distribution business,” with plans to launch a portfolio of 11 biosimilar products by 2028. In a 15 March letter to shareh

Israeli firm Kamada has announced entering into agreements with two undisclosed international pharmaceutical companies to market three biosimilar product candidates in Israel. Kamada will be respons

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker . Menarini To Pay $11.50 Per Share In